Synlogic Reports Second Quarter 2022 Financial Results and
– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...
Stay updated with breaking news from Synlogic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...
/PRNewswire/ -- The Microbiomes Market report offers information on several market vendors, including 4D pharma Plc, ENTEROME SA, Evelo Biosciences Inc.,...
The global microbiome therapeutics market is expected to exhibit an exponential CAGR of 62.9% during the forecast period 2018–2025.
Synlogic (NASDAQ:SYBX – Get Rating)‘s stock had its “buy” rating reissued by stock analysts at Chardan Capital in a report issued on Friday, TipRanks reports. They currently have a $9.00 price objective on the biotechnology company’s stock. SYBX has been the subject of several other research reports. Oppenheimer reduced their price target on shares of […]
Shares of Synlogic, Inc. (NASDAQ:SYBX – Get Rating) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year […]